Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs. Read More
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). These updates represent significant progress toward reaching the Company’s goal of bringing forward first-in-class or best-in-class therapies that target the underlying cause of these serious kidney diseases.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 20 years.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector.
